Difference between revisions of "Peginterferon alfa-2b (Sylatron)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
(updated content)
Line 1: Line 1:
−
Also known as Sylatron.
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway.  Also has been seen to activate NFκB (NF kappa B) in many cell types.  Interferon α-2b activates multiple biologic effects which are not fully understood.  Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/peginterferonalfa-2b.pdf Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway.  Also has been seen to activate NFκB (NF kappa B) in many cell types.  Interferon α-2b activates multiple biologic effects which are not fully understood.  Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.merck.com/product/usa/pi_circulars/s/sylatron/sylatron_pi.pdf Peginterferon alfa-2b (Sylatron) package insert]</ref><ref>[[Media:Peginterferonalfa-2b.pdf|Peginterferon alfa-2b (Sylatron) package insert (locally hosted backup)]]</ref><ref>[http://www.sylatron.com Sylatron manufacturer's website]</ref><ref name="pegintron">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[[Media:Peginterferonalfa-2bpegintron.pdf|Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)]]</ref><ref>[http://pegintron.com/ PegIntron manufacturer's website]</ref>
 
<br>Route: SC
 
<br>Route: SC
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is used==
 +
*[[Melanoma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/bio/peg_interferon.asp Peginterferon alfa-2b (PegIntron) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/peg_interferon.asp Peginterferon alfa-2b (PegIntron) patient drug information (Chemocare)]</ref>
+
*[http://chemocare.com/chemotherapy/drug-info/PEG-Interferon.aspx Peginterferon alfa-2b (Sylatron) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/PEG-Interferon.aspx Peginterferon alfa-2b (Sylatron) patient drug information (Chemocare)]</ref>
−
*[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-patient-drug-information Peginterferon alfa-2b (PegIntron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-patient-drug-information Peginterferon alfa-2b (PegIntron) patient drug information (UpToDate)]</ref>
+
*Patient counseling information can be found on [http://www.merck.com/product/usa/pi_circulars/s/sylatron/sylatron_pi.pdf#page=11 page 11 of the Peginterferon alfa-2b (Sylatron) package insert]<ref name="insert"></ref>
 +
*[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-patient-drug-information Peginterferon alfa-2b (Sylatron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-patient-drug-information Peginterferon alfa-2b (Sylatron) patient drug information (UpToDate)]</ref>
 +
 
 +
==History of changes in FDA indication==
 +
*1/19/2001: [http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/pegsche011901L.htm FDA approved] (as PegIntron) "for treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease."<ref name="pegintron"></ref>
 +
*3/29/2011: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm249263.htm FDA approved] "for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy."<ref name="insert"></ref>
 +
 
 +
==Also known as==
 +
Interferon Alfa-2b (PEG conjugate), PEG-INTRON, PegIntron, pegylated interferon alfa-2b.
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drug index]]
 +
[[Category:Immunotherapy]]
 +
[[Category:Melanoma medications]]

Revision as of 00:41, 20 June 2013

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to Interferon alfa-2b (Intron-A).[1][2][3][4][5][6]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1/19/2001: FDA approved (as PegIntron) "for treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease."[4]
  • 3/29/2011: FDA approved "for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy."[1]

Also known as

Interferon Alfa-2b (PEG conjugate), PEG-INTRON, PegIntron, pegylated interferon alfa-2b.

References

  1. ↑ 1.0 1.1 1.2 1.3 Peginterferon alfa-2b (Sylatron) package insert
  2. ↑ Peginterferon alfa-2b (Sylatron) package insert (locally hosted backup)
  3. ↑ Sylatron manufacturer's website
  4. ↑ 4.0 4.1 Peginterferon alfa-2b (PegIntron) package insert
  5. ↑ Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)
  6. ↑ PegIntron manufacturer's website
  7. ↑ Peginterferon alfa-2b (Sylatron) patient drug information (Chemocare)
  8. ↑ Peginterferon alfa-2b (Sylatron) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Peginterferon_alfa-2b_(Sylatron)&oldid=3214"